WASHINGTON (dpa-AFX) - Semiconductor manufacturer, Analog Devices, Inc.
(ADI), Tuesday announced the U.S. Food and Drug Administration or FDA 510(k)
clearance and commercial launch of Sensinel Cardiopulmonary Management or CPM
System, a non-invasive device that measures cardiopulmonary movements for
chronic disease management.

The Sensinel CPM system is equipped with a set of physiological indicators to
help care teams better manage chronic conditions early and remotely, as well as
in a precise manner.

The company explained that the device captures the cardiopulmonary movements of
patients and then uploads it to the Analog Devices's Sensinel CPM Cloud Platform
using a cellular link. Later, the data is analyzed using the company's Sensinel
CPM Intelligent Algorithms in the cloud.

Currently, Analog's stock is slipping 0.36 percent, to $193.95 on the Nasdaq.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX